Spiration grabs $18.5m to take IBV into US:
This article was originally published in Clinica
Executive Summary
Spiration's IBV valve system, a minimally-invasive device for treating acute and chronic lung disorders, is advancing towards the US market, after the Redmond, Washington firm closed an $18.5m series C financing. The funds will be used to complete clinical trials, which will support US FDA approval of the system. The new capital will also enable Spiration to expand commercialisation of the CE-marked IBV in Europe.